Differences in lung bioavailability between different propellants for fluticasone propionate

Lancet

Volumn 354, Issue 9187, 1999, Pages 1357-1358

  Wilson, Andrew M ^a   Sims, Erika J ^a   Orr, Linda C ^a   Lipworth, Brian J ^a  

^a Asthma and Allergy Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; CREATININE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; PROPELLANT;

ADRENAL SUPPRESSION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DATA ANALYSIS; DRUG BIOAVAILABILITY; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0033576137     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03581-3     Document Type: Article

References (3)

1. Wilson A.M., Lipworth B.J. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax. 54:1999;20-26.
2. Cripps A.L., Munro A.J., Boles M.G., Roche T.C., Sawyer S.E., Stevens J.C. Pharmaceutical evaluation of a new HFA-based metered dose inhaler for fluticasone propionate. J Aerosol Med. 10:1997;5-6. (abstr).
3. Ayres J., Millar A., Williams E. A twelve week multicentre study comparing the efficacy and tolerability of fluticasone propionate 2 mg daily propelled by chlorofluorocarbons 11 and 12 or an alternative propellant, GR106642X in adults with severe asthma. Eur Respir J. 8:1995;157. (suppl 19)(abstr).